Key Laboratory of Chinese Internal Medicine of Educational Ministry and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, 100700, Beijing, China.
Department of Stomatology, Dongzhimen Hospital, Beijing University of Chinese Medicine, 100700, Beijing, China.
J Ethnopharmacol. 2021 May 23;272:113943. doi: 10.1016/j.jep.2021.113943. Epub 2021 Feb 20.
Xuesaitong (XST) is a traditional Chinese medicine injection with neuroprotective properties and has been extensively used to treat stroke for many years. The main component of XST is Panax notoginseng saponins (PNS), which is the main extract of the Chinese herbal medicine Panax notoginseng.
In this study, we investigated whether XST provided long-term neuroprotection by inhibiting neurite outgrowth inhibitor-A (Nogo-A) and the ROCKII pathway in experimental rats after middle cerebral artery occlusion (MCAO) and in SH-SY5Y cells exposed to oxygen-glucose deprivation/reperfusion (OGD/R).
Rats with permanent MCAO were administered XST, Y27632, XST plus Y27632, and nimodipine for 14 and 28 days. Successful MCAO onset was confirmed by 2,3,5-triphenyl tetrazolium chloride (TTC) staining. Neurological deficit score (NDS) was used to assess neurological impairment. Hematoxylin-eosin (HE) staining and immunohistochemical (IHC) analysis of synaptophysin (SYN) and postsynaptic density protein-95 (PSD-95) were performed to evaluate cerebral ischemic injury and the neuroprotective capability of XST. Nogo-A levels and the ROCKII pathway were detected by IHC analysis, western blotting, and quantitative real-time polymerase chain reaction (qRT-PCR) to explore the protective mechanism of XST. OGD/R model was established in SH-SY5Y cells. Cell counting kit 8 (CCK8) was applied to detect the optimum OGD time and XST concentration. The expression levels Nogo-A and ROCKII pathway were determined using western blotting.
Our results showed that XST reduced neurological dysfunction and pathological damage, promoted weight gain and synaptic regeneration, reduced Nogo-A mRNA and protein levels, and inhibited the ROCKII pathway in MCAO rats. CCK8 assay displayed that the optimal OGD time and optimal XST concentration were 7 h and 20 μg/mL respectively in SH-SY5Y cells. XST could evidently inhibit OGD/R-induced Nogo-A protein expression and ROCKII pathway activation in SH-SY5Y cells.
The present study suggested that XST exerted long-term neuroprotective effects that assisted in stroke recovery, possibly through inhibition of the ROCKII pathway.
血塞通(XST)是一种具有神经保护特性的中药注射剂,多年来广泛用于治疗中风。XST 的主要成分是三七总皂苷(PNS),这是中药三七的主要提取物。
本研究通过观察血塞通对大脑中动脉闭塞(MCAO)大鼠及氧葡萄糖剥夺/再灌注(OGD/R)SH-SY5Y 细胞中神经生长抑制因子-A(Nogo-A)和 ROCKII 通路的抑制作用,探讨其是否具有长期神经保护作用。
对永久性 MCAO 大鼠给予血塞通、Y27632、血塞通加 Y27632 和尼莫地平治疗 14 天和 28 天。2,3,5-氯化三苯基四氮唑(TTC)染色证实 MCAO 成功。神经功能缺损评分(NDS)用于评估神经损伤。苏木精-伊红(HE)染色和突触素(SYN)和突触后密度蛋白-95(PSD-95)免疫组化(IHC)分析用于评估脑缺血损伤和血塞通的神经保护能力。通过 IHC 分析、western blot 和实时定量聚合酶链反应(qRT-PCR)检测 Nogo-A 水平和 ROCKII 通路,探讨血塞通的保护机制。在 SH-SY5Y 细胞中建立 OGD/R 模型。细胞计数试剂盒 8(CCK8)用于检测最佳 OGD 时间和血塞通浓度。western blot 检测 Nogo-A 和 ROCKII 通路的表达水平。
结果表明,血塞通可降低 MCAO 大鼠的神经功能障碍和病理损伤,促进体重增加和突触再生,降低 Nogo-A mRNA 和蛋白水平,抑制 ROCKII 通路。CCK8 检测显示,SH-SY5Y 细胞的最佳 OGD 时间和最佳血塞通浓度分别为 7 h 和 20 μg/mL。血塞通可明显抑制 OGD/R 诱导的 SH-SY5Y 细胞 Nogo-A 蛋白表达和 ROCKII 通路激活。
本研究表明,血塞通发挥长期神经保护作用,有助于中风恢复,可能通过抑制 ROCKII 通路。